Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
Antibiotic drug development is stuck in a rut. For decades, drug developers have been wary of the lack of a sustainable market for these life-saving drugs. Payers, meanwhile, have yet to figure out a reimbursement model that can entice drug developers to work in this space. Industry, as a result, has largely exited antibiotic R&D, and the pipeline for much needed antibiotics against multidrug-resistant bacteria is drying up. Now, in an attempt to change course, 24 pharmaceutical companies have launched a US$1 billion fund dedicated to antibiotic development.